Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Vaccines

Free Subscription Articles published in J Infect Dis Retrieve available abstracts of 179 articles: HTML format

Single Articles

June 2025
1. SONG Y, Deng B, Long CA, Li Q, et al
   Priming or Boosting P. falciparum Transmission Blocking Responses with Recombinant Vaccines or Gametocyte Extract.
   J Infect Dis. 2025 Jun 12:jiaf318. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. KNOX JJ, Lee I, Blumberg EA, Rosenfeld AM, et al
   B-Cell Subset Representation Predicts SARS-CoV-2 Vaccine Response in Solid Organ Transplant Recipients.
   J Infect Dis. 2025 Jun 3:jiaf250. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. NAYAGAM SN, Coote W, Carroll MT, Toh ZQ, et al
   Differentiating SARS-CoV-2 antibody responses between infection and vaccination: challenges for epidemiological research.
   J Infect Dis. 2025 Jun 3:jiaf295. doi: 10.1093.
   PubMed    
   
   
   May 2025
4. BAUM HE, Santopaolo M, Francis O, Milodowski EJ, et al
   Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough Infection After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Avon Longitudinal Study of Parents and Children (ALSPAC) Participants.
   J Infect Dis. 2025 May 20:jiaf246. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. ZHU S, Quint J, Leon T, Sun M, et al
   Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023-2024 Season.
   J Infect Dis. 2025 May 13:jiaf248. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. RUBENS JH, Brockhurst JK, Ghimire S, Wu J, et al
   Safety, immunogenicity, and protective efficacy in rhesus macaques of a novel recombinant hemagglutinin protein measles virus vaccine.
   J Infect Dis. 2025 May 13:jiaf244. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. ABDELKADER S, Jefferson AA
   Trust, A Key to Counter Vaccine Hesitancy.
   J Infect Dis. 2025 May 8:jiaf239. doi: 10.1093.
   PubMed    
   
   
   
8. 
   Correction to: Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older during the BA.1/BA.2 Omicron Period.
   J Infect Dis. 2025 May 6:jiaf137. doi: 10.1093.
   PubMed    
   
   
   April 2025
9. LAI SW, Liao KF
   Herpes zoster vaccine and cardiovascular disease risk.
   J Infect Dis. 2025 Apr 30:jiaf229. doi: 10.1093.
   PubMed    
   
   
   
10. XU X, Ray I, Tang E, Arnold BF, et al
    Authors' reply to Herpes zoster vaccine and cardiovascular disease risk.
    J Infect Dis. 2025 Apr 30:jiaf228. doi: 10.1093.
    PubMed    
    
    
    
11. ATMAR RL, Lyke KE, Posavad CM, Deming ME, et al
    Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
    J Infect Dis. 2025 Apr 29:jiaf176. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. CHEN H, Huang X, Wang C, Cowling BJ, et al
    Estimating the waning effectiveness of COVID-19 vaccines from population-level surveillance data in Hong Kong.
    J Infect Dis. 2025 Apr 18:jiaf207. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. CORTIER T, Gilboa M, Layan M, Joseph G, et al
    Factors Associated With the Transmission of the Delta Severe Acute Respiratory Syndrome Coronavirus 2 Variant in Households: The Israeli COVID-19 Family Study (ICoFS).
    J Infect Dis. 2025;231:e734-e742.
    PubMed     Abstract available
    
    
    
14. GRAY P, Wang J, Nordqvist Kleppe S, Elfstrom KM, et al
    Population-Based Age-Period-Cohort Analysis of Declining Human Papillomavirus Prevalence.
    J Infect Dis. 2025;231:e638-e649.
    PubMed     Abstract available
    
    
    
15. CHO HK, Frivold C, Chu HY
    Maternal Immunization.
    J Infect Dis. 2025;231:830-836.
    PubMed     Abstract available
    
    
    
16. YAMAMOTO S, Mizoue T, Ujiie M, Horii K, et al
    Low levels of post-vaccination hemagglutination inhibition antibodies and their correlation with influenza protection among healthcare workers during the 2024/2025 A/H1N1 outbreak in Japan.
    J Infect Dis. 2025 Apr 10:jiaf183. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. LEWIS NM, Harker EJ, Cleary S, Zhu Y, et al
    Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations-United States, September 1, 2023-May 31, 2024.
    J Infect Dis. 2025 Apr 8:jiaf185. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2025
18. WALSH EE, Peasley M, Branche A, Falsey AR, et al
    Respiratory Syncytial Virus (RSV) Humoral Antibody Responses in Older Adults after Vaccination or Infection.
    J Infect Dis. 2025 Mar 24:jiaf149. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. ROSTAD CA, Campbell JD, Paulsen GC, Schnyder Ghamloush S, et al
    Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age.
    J Infect Dis. 2025 Mar 22:jiaf144. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. FUJI N, Salamone FN, Kaur R, Bajorski P, et al
    Eighteen Year Longitudinal Study of Uncomplicated and Complex Acute Otitis Media during the Pneumococcal Conjugate Vaccine Era, 2006-2023.
    J Infect Dis. 2025 Mar 20:jiaf154. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. MENG Y, Lin Y, Xiong W, Lau EHY, et al
    Effective Real-time Transmission Estimations Incorporating Population Viral Load Distributions Amid SARS-CoV-2 Variants and Preexisting Immunity.
    J Infect Dis. 2025;231:684-691.
    PubMed     Abstract available
    
    
    
22. DASS S, Kundu P, Naskar D, Kanjee U, et al
    Miniaturized assay to evaluate Plasmodium cynomolgi and P. knowlesi as models for prioritizing P. vivax vaccine targets.
    J Infect Dis. 2025 Mar 14:jiaf136. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. HEDBERG P, van der Werff SD, Naucler P
    The effect of COVID-19 vaccination on the risk of persistent post COVID-19 condition: Cohort study.
    J Infect Dis. 2025 Mar 12:jiaf133. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. CHESSON HW, Markowitz LE
    Strong Herd Effects of Human Papillomavirus Vaccination.
    J Infect Dis. 2025 Mar 5:jiaf121. doi: 10.1093.
    PubMed    
    
    
    February 2025
25. WONG A, Warren JL, Fitch L, Perniciaro S, et al
    Estimating the serotype-specific association between the concentration of vaccine-induced serum antibodies and protection against pneumococcal colonization.
    J Infect Dis. 2025 Feb 28:jiaf106. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. XU X, Ray I, Tang E, Arnold BF, et al
    Protective Effects of Recombinant Zoster Vaccine and Antiviral Therapy Against Cardiovascular Disease Following Herpes Zoster Infection.
    J Infect Dis. 2025 Feb 28:jiaf105. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. GRANT LR, Sutcliffe CG, Littlepage S, Alexander-Parrish R, et al
    Persistence of vaccine serotype carriage and differences in pneumococcal carriage by lab method and sample type in Indigenous individuals in the Southwest USA.
    J Infect Dis. 2025 Feb 26:jiaf091. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. SMITH WB, Seger W, Chawana R, Jefferies Z, et al
    A Phase 2b Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 6-Valent Group B Streptococcus Vaccine Administered Concomitantly With Tetanus, Diphtheria, and Acellular Pertussis Vaccine in Healthy Nonpregnant Female Individuals.
    J Infect Dis. 2025 Feb 26:jiaf096. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. KANBAYASHI D, Kurata T, Kaida Y, Miyoshi T, et al
    How to Prevent Rubella Epidemics and Congenital Rubella Syndrome: Lessons From 42 Years of Longitudinal Epidemiology in Osaka Prefecture, Japan (1982-2023).
    J Infect Dis. 2025;231:440-450.
    PubMed     Abstract available
    
    
    
30. 
    Correction to: Natural Boosting and the Immunogenicity of the XBB.1.5 Monovalent Vaccine in the Coronavirus Disease 2019 Endemic Era: A Longitudinal Observational Study.
    J Infect Dis. 2025 Feb 17:jiaf073. doi: 10.1093.
    PubMed    
    
    
    
31. SOTO G, Romero C, Gonzales M, La Rosa S, et al
    Influenza Virus Surveillance in Healthcare Personnel in Peru: NAMRU SOUTH Experience and Perspective.
    J Infect Dis. 2025;231.
    PubMed     Abstract available
    
    
    
32. KOLLMANN TR, Amenyogbe N, Schaltz-Buchholzer F, Baek O, et al
    Is systemic dissemination of BCG following neonatal vaccination required for protection against M. tuberculosis?
    J Infect Dis. 2025 Feb 6:jiaf051. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. BARTHOLDSSON S, Hergens MP, Hansson KE, Ragnarsson J, et al
    Clinical Characteristics of Tick-Borne Encephalitis in Adult Patients: A 10-year Retrospective Study in Stockholm, Sweden.
    J Infect Dis. 2025;231:e195-e205.
    PubMed     Abstract available
    
    
    
34. PISANIC N, Antar AAR, Hetrich MK, Demko ZO, et al
    Early, Robust Mucosal Secretory Immunoglobulin A but not Immunoglobulin G Response to Severe Acute Respiratory Syndrome Coronavirus 2 Spike in Oral Fluid Is Associated With Faster Viral Clearance and Coronavirus Disease 2019 Symptom Resolution.
    J Infect Dis. 2025;231:121-130.
    PubMed     Abstract available
    
    
    
35. EL SAFADI D, Hitchins L, Howard A, Aley P, et al
    Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities.
    J Infect Dis. 2025;231:e17-e27.
    PubMed     Abstract available
    
    
    
36. JARA JH, Loayza S, Nogareda F, Couto P, et al
    Influenza vaccine averted illnesses in Chile, Guyana, and Paraguay during 2013-2018: a standardized approach to assess value of vaccination.
    J Infect Dis. 2025 Feb 1:jiaf038. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. DESCALZO MA, de Paula Junior FJ, Mallegas NV, Penayo E, et al
    Annual estimation of seasonal influenza burden in six South American countries: a retrospective analysis of SARInet surveillance data to inform policies.
    J Infect Dis. 2025 Feb 1:jiaf037. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2025
38. LAURENS MB
    Controlled human infection studies accelerate vaccine development.
    J Infect Dis. 2025 Jan 29:jiaf053. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. ASTORGA ALSINA AM, Herweijer E, Lei J
    Population-level Impact of HPV Vaccination on the Incidence of Genital Warts in Sweden.
    J Infect Dis. 2025 Jan 29:jiaf052. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. COOPER LV, Bandyopadhyay AS, Grassly NC, Gray EJ, et al
    Global Impact of Mass Vaccination Campaigns on Circulating Type 2 Vaccine-Derived Poliovirus Outbreaks: An Interrupted Time-Series Analysis.
    J Infect Dis. 2025 Jan 28:jiae614. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. OLAL C, Bodmer BS, Rottstegge M, Escudero-Perez B, et al
    Antibody-Based Antigen Delivery to Dendritic Cells as a Vaccination Strategy Against Ebola Virus Disease.
    J Infect Dis. 2025 Jan 14:jiae613. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. PICHICHERO ME, Gonzalez E, Cox A, Thayer TC, et al
    Variability in Vaccine Response and Trajectory in Early Childhood and Association with Demographic Variables, Antibiotic Exposure and Infection Proneness.
    J Infect Dis. 2025 Jan 11:jiaf023. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. CHALKIAS S, Pragalos A, Akinsola A, Berman G, et al
    Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain andN-Terminal Domain mRNA Vaccine.
    J Infect Dis. 2025 Jan 10:jiaf022. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. BILLINGS WZ, Ge Y, Knight JH, Hemme H, et al
    High dose inactivated influenza vaccine inconsistently improves heterologous antibody responses in an elderly human cohort.
    J Infect Dis. 2025 Jan 8:jiaf003. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. FELDSTEIN LR, Ruffin J, Wiegand RE, Borkowf CB, et al
    Effectiveness of mRNA COVID-19 vaccines and hybrid immunity in preventing SARS-CoV-2 infection and symptomatic COVID-19 among adults in the United States.
    J Infect Dis. 2025 Jan 8:jiaf007. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2024
46. BALIBAN SM, Shridhar S, Luo K, Kolasny J, et al
    A core glycolipid vaccine elicits cross-reactive antibodies against Salmonella spp. and protects against invasive nontyphoidal Salmonella disease in mice.
    J Infect Dis. 2024 Dec 31:jiae641. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. CHANDRASEKARAN P, Berry IM, Callier V, Anthony SM, et al
    Vector induced humoral responses after rVSVDeltaG-ZEBOV-GP immunization identify vaccinated individuals and correlate with Ebola virus glycoprotein antibodies.
    J Infect Dis. 2024 Dec 24:jiae632. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. FORCADELL-PERIS MJ, Vila-Corcoles A, de Diego-Cabanes C, Torras Vives V, et al
    Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in Adults: A Population-Based Study.
    J Infect Dis. 2024 Dec 16:jiae624. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. ATMAR RL, Ettayebi K, Neill FH, Braun RP, et al
    Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels.
    J Infect Dis. 2024;230:1376-1379.
    PubMed     Abstract available
    
    
    
50. CHAN JCH, Leung D, Chan SM, Tam IYS, et al
    Seroepidemiology of Measles and Rubella Among Hong Kong Young Adults and the Humoral Responses of a Measles-Mumps-Rubella Booster Among Participants With Low Antibody Levels.
    J Infect Dis. 2024;230:1367-1375.
    PubMed     Abstract available
    
    
    
51. HAMMERTON SM, Billings WZ, Hemme H, Ross TM, et al
    Estimating standard-dose and high-dose Fluzone vaccine efficacies for influenza A based on HAI titers.
    J Infect Dis. 2024 Dec 13:jiae615. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. WILSON GJ, Church LWP, Kelley CF, Robinson ST, et al
    HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines.
    J Infect Dis. 2024 Dec 13:jiae558. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2024
53. KANG HM, Kim HJ, Jung J, Ahn JY, et al
    Natural Boosting and the Immunogenicity of the XBB.1.5 Monovalent Vaccine in the Coronavirus Disease 2019 Endemic Era: A Longitudinal Observational Study.
    J Infect Dis. 2024 Nov 29:jiae536. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. BURNETT E, Umana J, Anwari P, Mujuru HA, et al
    Rotavirus vaccine effectiveness stratified by national-level characteristics: an introduction to the 24-country MNSSTER-V Project, 2007-2023.
    J Infect Dis. 2024 Nov 28:jiae597. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. 
    Expression of Concern: Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older during the BA.1/BA.2 Omicron Period.
    J Infect Dis. 2024 Nov 28:jiae549. doi: 10.1093.
    PubMed    
    
    
    
56. 
    Correction to: Half-life Estimation of Pertussis-Specific Maternal Antibodies in (Pre)Term Infants After In-Pregnancy Tetanus, Diphtheria, Acellular Pertussis Vaccination.
    J Infect Dis. 2024 Nov 25:jiae565. doi: 10.1093.
    PubMed    
    
    
    
57. LEE AR, Kim WJ, Choi H, Kim SH, et al
    Genotype III-Based Japanese Encephalitis Vaccines Exhibit Diminished Neutralizing Response to Re-emerging Genotype V.
    J Infect Dis. 2024 Nov 22:jiae589. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. ZHAI PY, Zang X, Jiang T, Feng J, et al
    Health and Economic Impacts of Introducing Vaccae and Enhanced Drug-Resistant Tuberculosis Management Strategies in China.
    J Infect Dis. 2024 Nov 22:jiae590. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. NYGARD S, Falkenthal T, Sture T, Lynge E, et al
    Impact of multi-cohort HPV vaccination on cervical cancer in women below 30 years of age: Lessons learned from the Scandinavian countries.
    J Infect Dis. 2024 Nov 21:jiae584. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. 
    Correction to: Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study.
    J Infect Dis. 2024 Nov 20:jiae564. doi: 10.1093.
    PubMed    
    
    
    
61. KAUR R, Gierke R, McGee L, Gonzalez E, et al
    Pneumococci Isolated From Children in Community-Based Practice Differ From Isolates Identified by Population- and Laboratory-Based Invasive Disease Surveillance.
    J Infect Dis. 2024;230:1243-1252.
    PubMed     Abstract available
    
    
    
62. COHEN C, du Plessis M, Martinson N, Moyes J, et al
    A potential platform for future vaccine trials identifies high incidence of symptomatic and asymptomatic influenza infection among children aged 6-23 months in South Africa.
    J Infect Dis. 2024 Nov 14:jiae550. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. HUANG X, Wu J, Xu J, Wang H, et al
    Mycobacterium tuberculosis Antigen Rv1471 Induces Innate Immune Memory and Adaptive Immunity against Infection.
    J Infect Dis. 2024 Nov 14:jiae572. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. MAK J, Khan S, Britton A, Rose S, et al
    Association of mRNA COVID-19 vaccination and reductions in Post-COVID Conditions following SARS-CoV-2 infection in a US prospective cohort of essential workers.
    J Infect Dis. 2024 Nov 13:jiae556. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. WATKINS TA, Brockhurst JK, Germain G, Griffin DE, et al
    Detection of live attenuated measles virus in the respiratory tract following subcutaneous MMR Vaccination.
    J Infect Dis. 2024 Nov 6:jiae537. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. YEGOROV S, Brewer A, Cyr L, Ward BJ, et al
    Hemagglutination-Inhibition Antibodies and Protection against Influenza Elicited by Inactivated and Live Attenuated Vaccines in Children.
    J Infect Dis. 2024 Nov 6:jiae489. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
67. LEROUX-ROELS I, Alhatemi A, Caubet M, De Boever F, et al
    Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study.
    J Infect Dis. 2024 Oct 24:jiae466. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. YOON KW, Chu KB, Eom GD, Mao J, et al
    CpG-adjuvanted virus-like particle vaccine induces protective immunity against Leishmania donovani infection.
    J Infect Dis. 2024 Oct 24:jiae526. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. MAVIAN CN, Tagliamonte MS, Bassett M, Alam M, et al
    COVID-19 lineages in a minimally vaccinated island population: Genomic epidemiology of SARS-CoV-2 in Haiti.
    J Infect Dis. 2024 Oct 23:jiae520. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. DIB SM, Tandon Wimalasena S, Graciaa DS, Rouphael N, et al
    Systems Vaccinology: Navigating the Future of Personalized Immunity and Next Generation Vaccines.
    J Infect Dis. 2024 Oct 19:jiae505. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. KNISELY JM, Erbelding E
    Vaccines for Global Health: Progress and Challenges.
    J Infect Dis. 2024 Oct 18:jiae511. doi: 10.1093.
    PubMed    
    
    
    
72. SELVERIAN CN, Monticelli SR, Jaleta YM, Lasso G, et al
    MPXV Infection Stimulates a More Robust and Durable Neutralizing Antibody Response Compared to MVA-BN Vaccination.
    J Infect Dis. 2024 Oct 18:jiae515. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. BABU TM, Jackson LA, El Sahly HM
    Next-Generation SARS-CoV-2 Vaccine Formulations and Alternative Routes of Administration.
    J Infect Dis. 2024 Oct 16:jiae504. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. SCHALTZ-BUCHHOLZER F, Nielsen S, Sorensen MK, Gomes GM, et al
    Maternal Bacille Calmette-Guerin Scars and Mortality Risk for Male and Female Newborns: Observational Study From Guinea-Bissau.
    J Infect Dis. 2024;230:995-1003.
    PubMed     Abstract available
    
    
    
75. HAGER DN, Zhu Y, Sohn I, Stubblefield WB, et al
    Effectiveness of the original monovalent mRNA COVID-19 vaccination series against hospitalization for COVID-19-associated venous thromboembolism.
    J Infect Dis. 2024 Oct 15:jiae502. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. LU Y, Matuska K, McEvoy R, Izurieta HS, et al
    Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older during the BA.1/BA.2 Omicron Period.
    J Infect Dis. 2024 Oct 15:jiae503. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. OKOLI GN, Cowling BJ
    Improved Methods for Vaccine Effectiveness Studies.
    J Infect Dis. 2024 Oct 15:jiae510. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. ISON MG
    Vaccines for Use in Special Populations: Immunocompromised Hosts.
    J Infect Dis. 2024 Oct 15:jiae508. doi: 10.1093.
    PubMed    
    
    
    
79. DOBRZYNSKI D, Branche AR, Falsey AR
    Combination seasonal vaccines for influenza, RSV, SARS-CoV-2, and other pathogens.
    J Infect Dis. 2024 Oct 15:jiae507. doi: 10.1093.
    PubMed    
    
    
    
80. CHU HY
    A Perspective on Vaccinology.
    J Infect Dis. 2024 Oct 14:jiae506. doi: 10.1093.
    PubMed    
    
    
    
81. LANGWORTHY K, Taggart M, Smith R, Levy A, et al
    Serological responses to target Streptococcus pyogenes vaccine antigens in patients with proven invasive beta-haemolytic streptococcal infections.
    J Infect Dis. 2024 Oct 9:jiae496. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. YAO T, Li Y, Zhang Y, Sun Y, et al
    Immunogenicity, safety, and persistence induced by triple- and standard-strength four-dose hepatitis B vaccination regimens in hemodialysis patients: A multicenter, randomized, parallel-controlled trial in Six cities in Shanxi Province.
    J Infect Dis. 2024 Oct 8:jiae494. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. BUTT AA, Yan P, Abou-Samra AB, Shaikh OS, et al
    COVID-19 Disease Incidence and Severity in Previously Infected Unvaccinated Compared with Previously Uninfected Vaccinated Persons.
    J Infect Dis. 2024 Oct 8:jiae484. doi: 10.1093.
    PubMed     Abstract available
    
    
    
84. DU QQ, Shi W, Yao KH
    Pneumococcal Disease Research Across All Age Groups: Advancing Comprehensive Vaccination Strategies.
    J Infect Dis. 2024 Oct 5:jiae483. doi: 10.1093.
    PubMed    
    
    
    
85. PUN J, Evans C, Chasekwa B, Church JA, et al
    Associations between Histo-Blood Group Antigen Status in Mother-Infant Dyads and Infant Oral Rotavirus Vaccine Immunogenicity in rural Zimbabwe.
    J Infect Dis. 2024 Oct 1:jiae456. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2024
86. MURUGAIAH V, Watson SJ, Cunliffe RF, Temperton NJ, et al
    A transgenic mouse with a humanised B cell repertoire mounts an antibody response to influenza infection and vaccination.
    J Infect Dis. 2024 Sep 24:jiae472. doi: 10.1093.
    PubMed     Abstract available
    
    
    
87. NGUYEN HC, Lal KG, Balinsky CA, Hontz RD, et al
    Informing the Need for a SARS-CoV-2 Booster Based on the Immune Responses Among Young Healthy Adults to Variants Circulating in Late 2023.
    J Infect Dis. 2024;230:645-656.
    PubMed     Abstract available
    
    
    
88. SALEEM AF, Kazi ZU, Zehra SM, Parkar S, et al
    Mucosal Immunity to Poliovirus in Children 0-15 Years of Age: A Community-Based Study in Karachi, Pakistan in 2019.
    J Infect Dis. 2024;230:736-740.
    PubMed     Abstract available
    
    
    
89. LIN LY, Gantner P, Li S, Su B, et al
    Unpredicted protective function of Fc-mediated inhibitory antibodies for HIV and SARS-CoV-2 vaccines.
    J Infect Dis. 2024 Sep 20:jiae464. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. BAHAKEL H, Spieker AJ, Hayek H, Schuster JE, et al
    Immunogenicity and Reactogenicity of High-dose or Standard-dose Influenza Vaccine in a Second Consecutive Influenza Season.
    J Infect Dis. 2024 Sep 16:jiae454. doi: 10.1093.
    PubMed     Abstract available
    
    
    
91. KUSTERS JMA, Schim van der Loeff MF, Heijne JCM, King AJ, et al
    Changes in Genital HPV Prevalence during 12 Years Girls-Only Bivalent HPV Vaccination: Results from a Biennial Repeated Cross-Sectional Study.
    J Infect Dis. 2024 Sep 13:jiae455. doi: 10.1093.
    PubMed     Abstract available
    
    
    
92. TANG Y, Boribong BP, Swank ZN, Demokritou M, et al
    COVID-19 mRNA vaccines induce robust levels of IgG but limited amounts of IgA within the oronasopharynx of young children.
    J Infect Dis. 2024 Sep 10:jiae450. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. MUNYEMANA JB, Kabayiza JC, Nilsson S, Andersson ME, et al
    Shigella and ETEC have replaced rotavirus as main causes of childhood diarrhea in Rwanda after ten years of rotavirus vaccination.
    J Infect Dis. 2024 Sep 9:jiae446. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. JANES H, Fisher LH, Kee JJ, Parameswaran L, et al
    Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.
    J Infect Dis. 2024 Sep 3:jiae400. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
95. BALGOVIND P, Aung E, Shilling H, Murray GL, et al
    Human papillomavirus prevalence among Australian men aged 18-35 years in 2015-2018 according to vaccination status and sexual preference.
    J Infect Dis. 2024 Aug 30:jiae412. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. SALAZAR JC, Radolf JD
    T-Cell Responses to Treponema pallidum Proteins in Blood and Skin to Advance Syphilis Vaccine Design: Learning From Nature.
    J Infect Dis. 2024;230:275-277.
    PubMed    
    
    
    
97. GOH YS, Fong SW, Hor PX, Loh CY, et al
    Variant-Specific IgA Protects Against Omicron Infection.
    J Infect Dis. 2024;230:e287-e291.
    PubMed     Abstract available
    
    
    
98. MARCHESE AM, Rousculp M, Macbeth J, Beyhaghi H, et al
    The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review.
    J Infect Dis. 2024;230:e496-e502.
    PubMed     Abstract available
    
    
    
99. JOHNSON EE, Hart TM, Fikrig E
    Vaccination to Prevent Lyme Disease: A Movement Towards Anti-Tick Approaches.
    J Infect Dis. 2024;230.
    PubMed     Abstract available
    
    
    
100. DESISTO CL, Winer RL, Querec TD, Dada D, et al
     Vaccine effectiveness against anal HPV among men who have sex with men aged 18-45 years attending sexual health clinics in three United States cities, 2018-2023.
     J Infect Dis. 2024 Aug 8:jiae394. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. CHOCHUA S, Beall B, Lin W, Tran T, et al
     The emergent invasive serotype 4 ST10172 strain acquires vanG type vancomycin-resistance element: A case of a 66-year-old with bacteremic pneumococcal pneumonia.
     J Infect Dis. 2024 Aug 8:jiae393. doi: 10.1093.
     PubMed     Abstract available
     
     
     
102. LEWNARD JA, Hong V, Grant LR, Ackerson BK, et al
     Association of pneumococcal conjugate vaccination with SARS-CoV-2 infection among older adult recipients of COVID-19 vaccines: a longitudinal cohort study.
     J Infect Dis. 2024 Aug 5:jiae387. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2024
103. ABARA WE, Kirkcaldy RD, Bernstein KT, Galloway E, et al
     Effectiveness of MenB-4C vaccine against gonorrhea: a systematic review and meta-analysis.
     J Infect Dis. 2024 Jul 31:jiae383. doi: 10.1093.
     PubMed     Abstract available
     
     
     
104. 
     Correction to: Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
     J Infect Dis. 2024;230:e219.
     PubMed    
     
     
     
105. CLARK RA, Sumner T, Weerasuriya CK, Bakker R, et al
     Estimating the Potential Public Health Value of BCG Revaccination.
     J Infect Dis. 2024;230:e139-e143.
     PubMed     Abstract available
     
     
     
106. HORN EK, Herrera-Restrepo O, Acosta AM, Simon A, et al
     The Burden of Hepatitis A Outbreaks in the United States: Health Outcomes, Economic Costs, and Management Strategies.
     J Infect Dis. 2024;230:e199-e218.
     PubMed     Abstract available
     
     
     
107. LIM WW, Feng S, Wong SS, Sullivan SG, et al
     Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections.
     J Infect Dis. 2024;230:152-160.
     PubMed     Abstract available
     
     
     
108. KALIZANG'OMA A, Swarthout TD, Mwalukomo TS, Kamng'ona A, et al
     Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction.
     J Infect Dis. 2024;230:e189-e198.
     PubMed     Abstract available
     
     
     
109. SCHWARZ TF, Hwang SJ, Ylisastigui P, Liu CS, et al
     Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.
     J Infect Dis. 2024;230:e102-e110.
     PubMed     Abstract available
     
     
     
110. TENFORDE MW, Weber ZA, Yang DH, DeSilva MB, et al
     Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023.
     J Infect Dis. 2024;230:141-151.
     PubMed     Abstract available
     
     
     
111. SUMNER KM, Yadav R, Noble EK, Sandford R, et al
     Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022.
     J Infect Dis. 2024;230:45-54.
     PubMed     Abstract available
     
     
     
112. FELL DB, Russell M, Fung SG, Swayze S, et al
     Effectiveness of Influenza Vaccination During Pregnancy Against Laboratory-Confirmed Seasonal Influenza Among Infants Under 6 Months of Age in Ontario, Canada.
     J Infect Dis. 2024;230:e80-e92.
     PubMed     Abstract available
     
     
     
113. BENNETT C, Rivers EJ, Woo W, Bloch M, et al
     Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.
     J Infect Dis. 2024;230:e4-e16.
     PubMed     Abstract available
     
     
     
114. JEAN BAPTISTE AE, Wagai J, Hahne S, Adeniran A, et al
     High-Resolution Geospatial Mapping of Zero-Dose and Underimmunized Children Following Nigeria's 2021 Multiple Indicator Cluster Survey/National Immunization Coverage Survey.
     J Infect Dis. 2024;230:e131-e138.
     PubMed     Abstract available
     
     
     
115. LEE K, Williams KV, Englund JA, Sullivan SG, et al
     The Potential Benefits of Delaying Seasonal Influenza Vaccine Selections for the Northern Hemisphere: A Retrospective Modeling Study in the United States.
     J Infect Dis. 2024;230:131-140.
     PubMed     Abstract available
     
     
     
116. CHONG EA, Kumashie KG, Chong ER, Fabrizio J, et al
     Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia.
     J Infect Dis. 2024;230:15-27.
     PubMed     Abstract available
     
     
     
117. CISZEWSKI J, Taniuchi M, Lee B, Colgate ER, et al
     Differences in Rotavirus Shedding and Duration by Infant Oral Rotavirus Vaccination Status in Dhaka, Bangladesh, 2011-2014.
     J Infect Dis. 2024;230:e75-e79.
     PubMed     Abstract available
     
     
     
118. ALESSANDRINI J, Cox J, de Pokomandy A, Hart TA, et al
     Prevalence of Oral Human Papillomavirus Infection Among Urban Gay, Bisexual, and Other Men Who Have Sex With Men in Canada, 2017-2019.
     J Infect Dis. 2024 Jul 23:jiae345. doi: 10.1093.
     PubMed     Abstract available
     
     
     
119. BLOOM N, Ramirez SI, Cohn H, Parikh UM, et al
     SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedback.
     J Infect Dis. 2024 Jul 22:jiae371. doi: 10.1093.
     PubMed     Abstract available
     
     
     
120. LACABARATZ C, Durand M, Wiedemann A, Foucat E, et al
     Innate and cellular immune response to the Ebola vaccine Ad26.ZEBOV, MVA-BN-Filo: an ancillary study of the EBL2001 phase II trial.
     J Infect Dis. 2024 Jul 16:jiae360. doi: 10.1093.
     PubMed     Abstract available
     
     
     
121. HILL-BATORSKI L, Weiner JA, Ackerman ME, Hatta Y, et al
     Intranasal M2SR (M2-deficient Single Replication) Influenza Vaccine Induces Broadly Reactive Mucosal Antibody Production in Adults.
     J Infect Dis. 2024 Jul 16:jiae361. doi: 10.1093.
     PubMed     Abstract available
     
     
     
122. GALAFA B, Chikaonda T, Kudowa E, Sichone S, et al
     Natural carriage of Streptococcus pneumoniae is associated with increased experimental pneumococcal carriage but reduced conjugate vaccine efficacy in a human challenge model.
     J Infect Dis. 2024 Jul 10:jiae341. doi: 10.1093.
     PubMed     Abstract available
     
     
     
123. CHIME N, Anspach B, Jain V, Laajalahti O, et al
     Phase 3 Study Assessing Lot-to-lot Consistency of RSVPreF3 Vaccine and its Immune Response, Safety, and Reactogenicity When Co-administered with FLU-D-QIV.
     J Infect Dis. 2024 Jul 5:jiae342. doi: 10.1093.
     PubMed     Abstract available
     
     
     
124. 
     Correction to: Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
     J Infect Dis. 2024 Jul 3:jiae336. doi: 10.1093.
     PubMed    
     
     
     
125. MCCARRON M, Yau TS, Griffin C, Marcenac P, et al
     Do pregnant persons want influenza vaccines? Knowledge, attitudes, perceptions, and practices toward influenza vaccines in 8 low- and middle-income countries.
     J Infect Dis. 2024 Jul 2:jiae340. doi: 10.1093.
     PubMed     Abstract available
     
     
     
126. 
     Correction to: Progress in Access and Oral Polio Vaccine Coverage Among Children Aged <5 Years in Polio Campaigns After the Political Change in Afghanistan.
     J Infect Dis. 2024 Jul 1:jiae334. doi: 10.1093.
     PubMed    
     
     
     June 2024
127. ANANWORANICH J, Lee IT, Ensz D, Carmona L, et al
     Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial.
     J Infect Dis. 2024 Jun 27:jiae329. doi: 10.1093.
     PubMed     Abstract available
     
     
     
128. GOSWAMI J, Baqui AH, Doreski PA, Perez Marc G, et al
     Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults.
     J Infect Dis. 2024 Jun 18:jiae316. doi: 10.1093.
     PubMed     Abstract available
     
     
     
129. LACOURSE SM, Wetzler EA, Aurelio MC, Escudero JN, et al
     Hybrid Immunity to SARS-CoV-2 During Pregnancy Provides More Durable Infant Antibody Responses Compared to Natural Infection Alone.
     J Infect Dis. 2024;229:1728-1739.
     PubMed     Abstract available
     
     
     
130. LEROUX-ROELS I, Maes C, Mancini F, Jacobs B, et al
     Safety and immunogenicity of a 4-component GMMA-based Shigella vaccine in healthy European adults: Stage 1 of a randomized, controlled phase I/II clinical trial.
     J Infect Dis. 2024 Jun 10:jiae273. doi: 10.1093.
     PubMed     Abstract available
     
     
     
131. AMSTUTZ A, Chammartin F, Audige A, Eichenberger AL, et al
     Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3).
     J Infect Dis. 2024 Jun 7:jiae291. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2024
132. RUIZ GARCIA Y, Marrazzo J, Martinon-Torres F, Workowski K, et al
     Urgent Need to Understand and Prevent Gonococcal Infection: From the Laboratory to Real-World Context.
     J Infect Dis. 2024 May 31:jiae289. doi: 10.1093.
     PubMed     Abstract available
     
     
     
133. GODIN A, Connor RI, Degefu HN, Rosato PC, et al
     Nasal and pharyngeal mucosal immunity to poliovirus in children following routine immunization with inactivated polio vaccine (IPV) in the United States of America.
     J Infect Dis. 2024 May 29:jiae264. doi: 10.1093.
     PubMed     Abstract available
     
     
     
134. TOWNSEND L, Gillespie P, McGrath J, Kenny C, et al
     Health Care Personnel Workdays Lost and Direct Health Care Salary Costs Incurred due to COVID-19 Infection in the Age of Widespread Vaccine Availability.
     J Infect Dis. 2024 May 21:jiae223. doi: 10.1093.
     PubMed     Abstract available
     
     
     
135. NJIFON HLM, Kenmoe S, Ahmed SM, Roussel Takuissu G, et al
     Epidemiology of Rotavirus in Humans, Animals, and the Environment in Africa: A Systematic Review and Meta-analysis.
     J Infect Dis. 2024;229:1470-1480.
     PubMed     Abstract available
     
     
     
136. LEE YS, Bang YJ, Yoo S, Park SI, et al
     Analysis of the Immunostimulatory Effects of Cytokine-Expressing Internal Ribosome Entry Site-Based RNA Adjuvants and Their Applications.
     J Infect Dis. 2024;229:1408-1418.
     PubMed     Abstract available
     
     
     
137. SMITH CL, Didion E, Aung H, Tamilselvan B, et al
     Longitudinal analysis of nursing home residents' T cell responses after SARS-CoV-2 mRNA vaccinations shows influence of biological sex and SARS-CoV-2 infection history.
     J Infect Dis. 2024 May 14:jiae234. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. MOTSOENENG BM, Dhar N, Nunes MC, Krammer F, et al
     Hemagglutinin stalk-specific Fc-mediated functions are associated with protection against influenza-illness after seasonal influenza vaccination in pregnant women.
     J Infect Dis. 2024 May 14:jiae241. doi: 10.1093.
     PubMed     Abstract available
     
     
     
139. PERSSON KEM, Horton JL, Kurtovic L, McCarthy JS, et al
     Declining antibody affinity over time after human vaccination with a Plasmodium falciparum merozoite vaccine candidate.
     J Infect Dis. 2024 May 9:jiae259. doi: 10.1093.
     PubMed     Abstract available
     
     
     
140. HOY G, Stadlbauer D, Balmaseda A, Kuan G, et al
     Humoral correlates of protection against influenza A H3N2 virus infection.
     J Infect Dis. 2024 May 9:jiae258. doi: 10.1093.
     PubMed     Abstract available
     
     
     
141. EBINGER JE, Sun N, Joung SY, Sanchez JMS, et al
     Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Following Prior Infection or Vaccination.
     J Infect Dis. 2024 May 8:jiae130. doi: 10.1093.
     PubMed     Abstract available
     
     
     
142. BALASINGAM S, Dheda K, Fortune S, Gordon SB, et al
     Review of the current TB human infection studies for use in accelerating TB vaccine development: A meeting report.
     J Infect Dis. 2024 May 6:jiae238. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2024
143. BI Q, Dickerman BA, Nguyen HQ, Martin ET, et al
     Reduced effectiveness of repeat influenza vaccination: distinguishing among within-season waning, recent clinical infection, and subclinical infection.
     J Infect Dis. 2024 Apr 30:jiae220. doi: 10.1093.
     PubMed     Abstract available
     
     
     
144. JUHL AK, Lokso Dietz L, Schmeltz Sogaard O, Reekie J, et al
     Longitudinal evaluation of SARS-CoV-2 T cell immunity over 2 years following vaccination and infection.
     J Infect Dis. 2024 Apr 30:jiae215. doi: 10.1093.
     PubMed     Abstract available
     
     
     
145. SIRIVICHAYAKUL C, Biswal S, Saez-Llorens X, Lopez-Medina E, et al
     Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination.
     J Infect Dis. 2024 Apr 29:jiae222. doi: 10.1093.
     PubMed     Abstract available
     
     
     
146. ORUMAA M, Lahlum EJ, Gulla M, Tota J, et al
     Quadrivalent HPV vaccine effectiveness against cervical intraepithelial lesion grade 2 or worse in Norway: A registry-based study of 0,9 million Norwegian women.
     J Infect Dis. 2024 Apr 25:jiae209. doi: 10.1093.
     PubMed     Abstract available
     
     
     
147. 
     Correction to: Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
     J Infect Dis. 2024 Apr 18:jiae186. doi: 10.1093.
     PubMed    
     
     
     
148. NIKITIN D, Whittles LK, Imai-Eaton JW, White PJ, et al
     Cost-effectiveness of 4CMenB vaccination against gonorrhea: importance of dosing schedule, vaccine sentiment, targeting strategy, and duration of protection.
     J Infect Dis. 2024 Apr 17:jiae123. doi: 10.1093.
     PubMed     Abstract available
     
     
     
149. COHEN MS, Marrazzo J
     What if We Had a Vaccine that Prevents Neisseria gonorrhoeae.
     J Infect Dis. 2024 Apr 17:jiae160. doi: 10.1093.
     PubMed    
     
     
     
150. WALSH EE, Falsey AR, Zareba AM, Jiang Q, et al
     Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination.
     J Infect Dis. 2024 Apr 12:jiae185. doi: 10.1093.
     PubMed     Abstract available
     
     
     
151. UZZELL CB, Abraham D, Rigby J, Troman CM, et al
     Environmental Surveillance for Salmonella Typhi and its Association With Typhoid Fever Incidence in India and Malawi.
     J Infect Dis. 2024;229:979-987.
     PubMed     Abstract available
     
     
     
152. SCHMIDT S, Mengistu M, Daffis S, Ahmadi-Erber S, et al
     Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus-Specific CD8 T-Cell Responses and High Anti-Hepatitis B Surface Antigen Titers.
     J Infect Dis. 2024;229:1077-1087.
     PubMed     Abstract available
     
     
     
153. THOMPSON KM, Kalkowska DA, Routh JA, Brenner IR, et al
     Modeling Poliovirus Transmission and Responses in New York State.
     J Infect Dis. 2024;229:1097-1106.
     PubMed     Abstract available
     
     
     
154. SABAWOON W, Seino S, Pason BM, Momin NWS, et al
     Progress in Access and Oral Polio Vaccine Coverage Among Children Aged <5 Years in Polio Campaigns After the Political Change in Afghanistan.
     J Infect Dis. 2024 Apr 10:jiae129. doi: 10.1093.
     PubMed     Abstract available
     
     
     
155. CHEN MH, Perelygina L, Hao L, Beard RS, et al
     Neutralization of Rubella Vaccine Virus and Immunodeficiency-Related Vaccine-Derived Rubella Viruses by Intravenous Immunoglobulins.
     J Infect Dis. 2024 Apr 9:jiae182. doi: 10.1093.
     PubMed     Abstract available
     
     
     
156. PONZILACQUA-SILVA B, Dadelahi AS, Abushahba MFN, Moley CR, et al
     Vaccine Elicited Antibodies Restrict Glucose Availability to Control Brucella Infection.
     J Infect Dis. 2024 Apr 8:jiae172. doi: 10.1093.
     PubMed     Abstract available
     
     
     
157. BARTSCH SM, O'Shea KJ, Weatherwax C, Strych U, et al
     What is the economic benefit of annual COVID-19 vaccination from the adult individual perspective?
     J Infect Dis. 2024 Apr 6:jiae179. doi: 10.1093.
     PubMed     Abstract available
     
     
     
158. TAIT D, Diacon A, Borges AH, van Brakel E, et al
     Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial.
     J Infect Dis. 2024 Apr 1:jiae170. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2024
159. KAO CM, Rostad CA, Nolan LE, Peters E, et al
     A Phase 1, Double-blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin(R)) Vaccine in Healthy US Adults.
     J Infect Dis. 2024 Mar 27:jiae148. doi: 10.1093.
     PubMed     Abstract available
     
     
     
160. KALIZANG'OMA A, Swarthout TD, Mwalukomo TS, Kamng'ona A, et al
     Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction.
     J Infect Dis. 2024 Mar 26:jiae040. doi: 10.1093.
     PubMed     Abstract available
     
     
     
161. FIGUEROA AL, Azzi JR, Eghtesad B, Priddy F, et al
     Safety and Immunogenicity of the mRNA-1273 COVID-19 Vaccine in Solid Organ Transplant Recipients.
     J Infect Dis. 2024 Mar 21:jiae140. doi: 10.1093.
     PubMed     Abstract available
     
     
     
162. PRUNAS O, Shioda K, Toscano CM, Bastias M, et al
     Estimated population-level impact of pneumococcal conjugate vaccines against all-cause pneumonia mortality among unvaccinated age groups in five Latin American countries.
     J Infect Dis. 2024 Mar 19:jiae144. doi: 10.1093.
     PubMed     Abstract available
     
     
     
163. KING LM, Andrejko KL, Kabbani S, Tartof SY, et al
     Outpatient visits and antibiotic use due to higher valency pneumococcal vaccine serotypes.
     J Infect Dis. 2024 Mar 18:jiae142. doi: 10.1093.
     PubMed     Abstract available
     
     
     
164. PRASAD AN, Geisbert TW
     A glass-half-full perspective on negative data in Ebolavirus vaccine studies.
     J Infect Dis. 2024 Mar 15:jiae109. doi: 10.1093.
     PubMed    
     
     
     
165. VAN TOL S, Fletcher P, Feldmann F, Mukesh RK, et al
     A bivalent Adenovirus-Vectored Vaccine induces a robust humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus.
     J Infect Dis. 2024 Mar 15:jiae056. doi: 10.1093.
     PubMed     Abstract available
     
     
     
166. ROSSLER A, Knabl L, Netzl A, Bante D, et al
     Durability of Cross-Neutralizing Antibodies 5.5 Months After Bivalent Coronavirus Disease 2019 Vaccine Booster.
     J Infect Dis. 2024;229:644-647.
     PubMed     Abstract available
     
     
     
167. GRUNER E, Grossegesse M, Stern D, Ober V, et al
     Mpox-specific immune responses elicited by vaccination or infection in people living with HIV.
     J Infect Dis. 2024 Mar 13:jiae138. doi: 10.1093.
     PubMed     Abstract available
     
     
     
168. FIERRO C, Brune D, Shaw M, Schwartz H, et al
     Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1, Randomized, Clinical Trial.
     J Infect Dis. 2024 Mar 13:jiae114. doi: 10.1093.
     PubMed     Abstract available
     
     
     
169. MUNK C, Reinholdt K, Kjaer AK, Hemmingsen CH, et al
     Prevalence of Human Papillomavirus (HPV) and HPV Type Distribution in Penile Samples in Young Men in Denmark: Results 10 Years After Implementation of a Girls-Only HPV Vaccination Program.
     J Infect Dis. 2024 Mar 12:jiae068. doi: 10.1093.
     PubMed     Abstract available
     
     
     
170. SEPULVEDA-PACHON IT, Dunne EM, Hanquet G, Baay M, et al
     Effect of pneumococcal conjugate vaccines on viral respiratory infections: a systematic literature review.
     J Infect Dis. 2024 Mar 11:jiae125. doi: 10.1093.
     PubMed     Abstract available
     
     
     
171. LIM WW, Shuo F, Wong SS, Sullivan SG, et al
     Hemagglutination inhibition antibody titers mediate influenza vaccine efficacy against symptomatic influenza A(H1N1), A(H3N2), and B/Victoria infections.
     J Infect Dis. 2024 Mar 7:jiae122. doi: 10.1093.
     PubMed     Abstract available
     
     
     
172. COLON W, Oriol Mathieu V, Hural J, Hattingh L, et al
     HIV Diagnostics and Vaccines: It Takes Two to Tango.
     J Infect Dis. 2024 Mar 7:jiae113. doi: 10.1093.
     PubMed     Abstract available
     
     
     
173. WESTERCAMP N, Osei-Tutu L, Schuerman L, Kariuki SK, et al
     Could less be more? Accounting for fractional-dose regimens and different number of vaccine doses when measuring the impact of the RTS, S/AS01E malaria vaccine.
     J Infect Dis. 2024 Mar 4:jiae075. doi: 10.1093.
     PubMed     Abstract available
     
     
     
174. CHONG EA, Kumashie KG, Chong ER, Fabrizio J, et al
     Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
     J Infect Dis. 2024 Mar 4:jiae106. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2024
175. CAO Y, Hayashi CTH, Kumar N
     A novel ex vivo assay to evaluate functional effectiveness of Plasmodium vivax transmission blocking vaccine using Pvs25 transgenic P. berghei.
     J Infect Dis. 2024 Feb 26:jiae102. doi: 10.1093.
     PubMed     Abstract available
     
     
     
176. WANTUCH PL, Knoot CJ, Robinson LS, Vinogradov E, et al
     A heptavalent O-antigen bioconjugate vaccine exhibits differential functional antibody responses against diverse Klebsiella pneumoniae isolates.
     J Infect Dis. 2024 Feb 24:jiae097. doi: 10.1093.
     PubMed     Abstract available
     
     
     
177. DZIADULA J, Sabbaj S, Gupta K, Cutter G, et al
     Interferon-Gamma Responses to Chlamydia trachomatis Vaccine Candidate Proteins in Chlamydia-Infected Women with Different Chlamydia Outcomes.
     J Infect Dis. 2024 Feb 23:jiae092. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2023
178. BLAZEVIC A, Edwards RL, Xia M, Eickhoff CS, et al
     Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guerin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
     J Infect Dis. 2023 Nov 29:jiad441. doi: 10.1093.
     PubMed     Abstract available
     
     
     
179. GIULIANO AR, Palefsky JM, Goldstone SE, Dubin B, et al
     High Risk of New HPV Infection Acquisition Among Unvaccinated Young Men.
     J Infect Dis. 2023 Nov 28:jiad485. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.